Now let me write the final review.

## Summary

This paper evaluates small LMs/VLMs (≤3B params) against larger medically-adapted models on two clinical tasks: text summarization (MeQSum) and radiology report generation (MIMIC-CXR). It finds that with LoRA fine-tuning, small LMs can match or exceed larger models on text metrics, identifies a "safety collapse" at sub-billion parameter scales where hallucination rates spike sharply, and finds that small VLMs consistently lag behind larger ones for radiology reporting. The paper introduces a four-dimensional "Collapse Analysis" framework.

## Strengths

- **Safety collapse finding (Table 3) is genuinely informative and practically useful.** The paper demonstrates across two model families (SmolLM2, Gemma-3) and multiple parameter scales that hallucination rates spike catastrophically below roughly 500M–1B parameters. The four-dimensional analysis (Task Adherence, Hallucination Rate, Concept Recall, Prompt Robustness) is more granular than a single aggregate metric, and this granularity produces concrete guidance for edge deployment decisions.

- **Honest reporting of divergent results across modalities.** The paper evaluates both text-only and vision-language tasks and finds opposite outcomes: small LMs can be competitive on text summarization under certain conditions, while small VLMs uniformly fall short on radiology. Reporting both results — rather than suppressing the negative finding — strengthens credibility.

- **Appropriate domain-specific metrics.** Including MEDCON (UMLS-based concept coverage) alongside standard n-gram and embedding metrics is well-motivated for clinical NLP, where capturing the right medical concepts matters more than surface-form overlap.

## Weaknesses

### Fatal
None.

### Major

1. **Asymmetric comparison undermines the central "outperforms large models" claim.** The paper's headline finding — repeatedly stated as "exceeds," "outperforms," and "surpasses" larger medical LMs (abstract line 17, lines 150–151, line 191, line 231, line 243, line 247) — is built on comparing **LoRA-fine-tuned small models** against **large models evaluated only via in-context learning** (zero-shot or few-shot). The paper explicitly states that fine-tuning was applied only to enhance small-model capabilities (line 120: *"To further enhance small-model capabilities, we applied three parameter-efficient fine tuning methods"*), and Figure 3 shows large models with no LoRA bars (marked "-"). The large models were neither LoRA-fine-tuned nor otherwise adapted on the MeQSum training set.

   Comparing a fine-tuned model against a non-fine-tuned baseline conflates the effect of task-specific adaptation with model capacity. The title question — *"Is model size a barrier to quality?"* — cannot be answered from this design. The fair comparison (Table 2, zero-shot vs. zero-shot) shows far more modest results: SmolLM2 is competitive with large models on BERTScore and MEDCON but not clearly superior. To support the headline claim, the paper would need LoRA-fine-tuned large model baselines, or must honestly reframe the finding as "LoRA-fine-tuned small LMs match/exceed ICL-based large LMs."

2. **No variance or significance reporting.** All tables present point estimates from what appears to be a single run on a fixed 250-sample test set (line 82), despite using stochastic decoding (top-k with k=3, top-p with p=0.9, temperature T=0.3; line 78). Differences as small as BERTScore 0.9007 vs. 0.8938 (Table 2) are discussed comparatively ("surpassed," "exceeded") without confidence intervals, error bars, or statistical significance tests. The reader cannot assess whether observed differences reflect genuine effects or sampling noise.

3. **Safety threshold claim overstates precision; "Readiness Score" undefined.** Table 3 covers only two model families (SmolLM2 with 4 sizes, Gemma-3 with 3 sizes). The threshold varies between them: SmolLM2 degrades between 1.7B (3.5% hallucination) and 360M (18.3%), while Gemma-3 holds at 1B (2.9%) and collapses at 270M (75%). Claiming "approximately 1B parameters" (Table 3 caption) overstates precision; the evidence supports a range (~500M–1.7B). Additionally, the "Readiness Score" column in Table 3 is never defined or derived anywhere in the paper, making it uninterpretable.

4. **Undefined terms and internal inconsistencies.** The "MeQ-Small corpus" (line 231) is mentioned as the fine-tuning training set but never defined — it is unclear whether this is a subset of MeQSum or a separate resource. Table 3 lists "SmolLM3-3B" as the first model entry, but no SmolLM3 model appears in Table 1 or anywhere else in the paper (only SmolLM2 is discussed). These gaps affect reproducibility.

### Minor

1. **Figure 2 caption omits comparison context.** The caption states that LoRA-tuned LLaMA-3.2 1B "exceeds" large models on several metrics but does not clarify that the large model scores shown are ICL scores, not LoRA scores. This risks misleading readers about the nature of the comparison.

2. **Fine-tuning hyperparameters unreported.** No LoRA rank, alpha, target modules, learning rate, number of epochs, or batch size are provided beyond the cross-entropy loss formula (lines 140–144). This limits reproducibility of the fine-tuning results.

3. **Fine-tuning status of large VLMs in Table 4 is ambiguous.** The paper states "After fine-tuning, we benchmarked these small VLMs against two large VLMs" (line 237), but does not specify whether Med-Flamingo and LLaVA-Med were also fine-tuned on MIMIC-CXR or used off-the-shelf. This affects interpretation of the comparison.

### Trivial
None.

## Nice-to-Haves

- **Human evaluation.** The paper itself cites Aali et al. (2025) noting that physicians prefer larger models even when automated metrics are similar (lines 48–51), which partially undercuts the practical significance of metric parity. A small human evaluation would strengthen the practical claims.
- **Fine-tuning large models with LoRA** on the same data would transform the asymmetric comparison into a fair test and could yield a genuinely striking result.
- **Reporting the safety threshold as a range** (~500M–1.7B) rather than a single "1B" value would better reflect the evidence.

## Removed Points
These points from the input review were filtered per the merging guidelines:
- **"Table ?? reference (line 219)"**: Removed as likely a parsing artifact from LaTeX cross-reference resolution; the original PDF would show a proper table number.
- **"Instruction prompt is ~45 words exceeding the ≤30 word limit"**: Removed as a style nitpick that does not affect the paper's claims.
- **"No human evaluation" (as a core weakness)**: Downgraded to Nice-to-Have because the paper explicitly scopes itself to automated metrics and acknowledges this limitation in its related work section.
- Missing appendix content criticisms: Removed per guidelines; appendices are stripped by the parser and may exist in the original submission.

## Novel Insights
None beyond the paper's own contributions. The reviewer observations about the asymmetric comparison, while valid, are a straightforward reading of the experimental design rather than a novel insight.

## Suggestions

1. **Reframe the central claim** to honestly disclose the asymmetry: e.g., "LoRA-fine-tuned small LMs match or exceed ICL-based large medical LMs on text summarization metrics." This is still a valuable finding but requires accurate framing.
2. **Add bootstrap confidence intervals** (even from resampling the 250 test samples) to all quantitative comparisons.
3. **Define the Readiness Score** computation and the **MeQ-Small** corpus explicitly.
4. **Clarify the fine-tuning status** of Med-Flamingo and LLaVA-Med in the radiology experiments.
5. **Present the safety threshold as a range** rather than a single precise value.

**Calibration anchors (all retrieved across rounds):**

| Path | Avg Human Score | Round | Comparison |
|------|----------------|-------|------------|
| 8QTpYC4smR.md (Systematic Review of LLMs) | 1.00 | R1 (strong reject) | Not comparable; a survey paper with no experiments |
| koza5fePTs.md (Planning Capabilities of LLMs) | 2.00 | R1 (reject) | Cleaner evaluation but limited novelty |
| jgVqCCg5XX.md (Scaling Effects of LLMs on Medical Reasoning) | 4.00 | R1/R2 (reject) | Most comparable: similar topic (medical scaling), same missing-CI issue; our paper has a more useful finding (safety collapse) but a more serious design flaw (asymmetric comparison) |
| gYcft1HIaU.md (Do Current LLMs Master Clinical Knowledge?) | 4.33 | R2 (reject) | Similar empirical benchmarking; cleaner comparison setup but less actionable findings |
| MEztAJjcYZ.md (Enhancing Clinical Note Summarization) | 4.25 | R2 (reject) | Method paper with different scope |
| juStNETXI5.md (Tiny-StyleWizard) | 3.75 | R2 (reject) | Different task domain |
| o9SuQXZvNA.md (ClinicalBench) | 5.50 | R2 (reject) | Similar benchmarking paper with cleaner comparison; rejected partly for predictable findings; our paper has more novel findings but a more serious methodological flaw |
| 4xBew7kuYB.md (Studying Effects of Training Data on SLMs) | 5.50 | R2 (reject) | Empirical SLM study; rejected for limited insights; our paper has stronger practical guidance |
| tFwEsrx1hm.md (Fallback Behaviors of LMs) | 5.75 | R1 (reject) | Empirical analysis of hallucination/fallback; similar nature but different domain; our paper has less rigorous uncertainty characterization |
| ztpy1gsUpT.md (Enhancing Small Medical Learners) | 6.00 | R1 (accept) | Method paper with clean experimental design; stronger than our paper methodologically |

**Round 1 bracket:** 4.0–5.5. **Narrowing:** The ClinicalBench paper (5.5, Reject) had a cleaner experimental design but less useful findings; our paper has a more useful finding (safety collapse) but a more serious methodological flaw. Placing the paper below 5.0 given the structural issue. Several 4.0–4.5 anchors on related topics corroborate this range.

**Final Score:** 4.5
**Final Decision:** Reject

The paper addresses an important practical question and contains a genuinely useful finding (the safety collapse at sub-billion scales). However, the central comparative claim — that small models "exceed" large ones — is not supported by the evidence due to an asymmetric experimental design (fine-tuned small vs. non-fine-tuned large). Combined with the absence of variance reporting and several undefined terms, these issues prevent acceptance in the current form. The safety collapse analysis could be salvageable as a standalone contribution, and the paper's honest radiology results are informative. With substantial revision — particularly reframing the central claim and adding proper uncertainty quantification — the paper could become a solid contribution.

MY FINAL SCORE: <score>4.5</score>
MY FINAL DECISION: <decision>Reject</decision>